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ABSTRACT
Background: Cancer patients often report behavioral and cognitive changes following
cancer treatment. These effects can be seen in patients who have not yet received treatment
or have received only peripheral (non-brain) irradiation. Novel treatments combining
radiotherapy (RT) and immunotherapy (IT) demonstrate remarkable efficacy with respect
to tumor outcomes by enhancing the proinflammatory environment in the tumor. However,
a proinflammatory environment in the brain mediates cognitive impairments in other
neurological disorders and may affect brain function in cancer patients receiving these
novel treatments. Currently, gaps exist as to whether these treatments impact the brain
in individuals with or without tumors and with regard to the underlying mechanisms.
Results: Combined treatment with precision RT and checkpoint inhibitor IT
achieved control of tumor growth. However, BALB/c mice receiving combined treatment
demonstrated changes in measures of anxiety levels, regardless of tumor status.
C57BL/6J mice with tumors demonstrated increased anxiety, except following combined
treatment. Object recognition memory was impaired in C57BL/6J mice without tumors
following combined treatment. All mice with tumors showed impaired object recognition,
except those treated with RT alone. Mice with tumors demonstrated impaired amygdaladependent cued fear memory, while maintaining hippocampus-dependent context fear
memory. These behavioral alterations and cognitive impairments were accompanied by
increased microglial activation in mice receiving immunotherapy alone or combined with
RT. Finally, based on tumor status, there were significant changes in proinflammatory
cytokines (IFN-γ, IL-6, IL-5, IL-2, IL-10) and a growth factor (FGF-basic).
Materials and Methods: Here we test the hypothesis that IT combined with
peripheral RT have detrimental behavioral and cognitive effects as a result of an
enhanced proinflammatory environment in the brain. BALB/c mice with or without
injected hind flank CT26 colorectal carcinoma or C57BL/6J mice with or without
Lewis Lung carcinoma were used for all experiments. Checkpoint inhibitor IT, using
an anti-CTLA-4 antibody, and precision CT-guided peripheral RT alone and combined
were used to closely model clinical treatment. We assessed behavioral and cognitive
performance and investigated the immune environment using immunohistochemistry
and multiplex assays to analyze proinflammatory mediators.
Conclusions: Although combined treatment achieved tumor growth control, it
affected the brain and induced changes in measures of anxiety, cognitive impairments,
and neuroinflammation.
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INTRODUCTION

Immunotherapeutics have been developed based on
findings that show that the immune environment in a tumor
prior to treatment is associated with clinical outcomes in
many cancers [33, 34]. An enhanced proinflammatory
tumor environment is associated with increased survival
following conventional cancer therapy, while antiinflammatory tumor profiles are associated with severely
limited survival [33, 3 4]. Given that radiation therapy has
also been implicated as an immune modulator, combined
immunotherapy and radiation treatment provides an
exciting synergistic possibility to initiate and amplify a
beneficial anti-tumor response [16, 24, 35–37].
One immunotherapy demonstrating robust results in
combination with radiation treatment involve antibodies
against CTLA4 (anti-CTLA4), a checkpoint inhibitor.
Anti-CTLA4 induces a proinflammatory environment
characterized by increased immune infiltrates in the tumor
and combines with radiation therapy to form protective
immunity [36, 38]. Pre-treatment with anti-CTLA4
antibodies before radiation therapy is optimal for tumor
control in preclinical models [39] and is consistent with
successful clinical anecdotes [40, 41] and a retrospective
review [42]. Importantly, patients are currently
being treated and experiencing sustained remissions
with the combination of radiation therapy and antiCTLA4 immunotherapy [25, 40, 41]. These treatments
demonstrate remarkable efficacy with respect to tumor
outcomes. However, how these treatments may affect the
immune environment in the brain, and behavioral and
cognitive outcome measures, is unknown. As yet, very
little is understood about the effects of these treatments
on the brain, either in healthy individuals or in individuals
with tumors, although fatigue has been reported [43, 44].
Clinical studies on cancer-related neurological
dysfunction have been limited by the presence of
numerous confounders, including genetic variability and
related differences in immune function between patients.
Mouse tumor models present a unique opportunity to study
the consequences of cancer and cancer treatment on brain
function in a controlled environment. Establishing a mouse
model also allows studying behavioral and cognitive
performance alongside tissue and molecular markers.
The choice of a subcutaneous tumor model in multiple
cell lines allows for precise and reliable comparison of all
groups at each stage of tumor development, as compared
to a spontaneous tumor model. Placement of the tumor
on the hind flank also allows for the best understanding
of immunological effects of peripheral radiation while
avoiding direct damage to healthy tissues or vasculature
that may otherwise confound results due to direct or
indirect effects of vascular changes on CNS function [45].
The current study represents an approach to model
cancer-related neurological dysfunction in two important
ways. First, although previous models have examined the
effects of tumor alone [46, 47], chemotherapy [48, 49],
peripheral radiation in healthy mice [11], direct immune

Behavioral and cognitive impairments are a
common and devastating complication of cancer and
cancer treatment [1–3]. These impairments often include
difficulty concentrating, memory impairments, fatigue,
and increased anxiety [4]. Cancer-related behavioral
changes and cognitive impairments often last well beyond
treatment, with up to 35% of patients reporting effects
lasting months or years [5]. Given improved cancer
outcomes and long-term survivorship, these impairments
are becoming increasingly important to study. Cancerrelated neurological dysfunction, which may contribute to
a suboptimal functional quality of life, has been widely
reported in human patients, yet the underlying mechanisms
remain elusive.
Historically, these impairments have been associated
with cytotoxic chemotherapy (“chemobrain”). However,
these changes have also been identified in patients who
have not yet received treatment or received peripheral
(non-brain) radiation alone, demonstrating that these
changes are most likely multifactorial [6–10]. One such
factor that has come under recent scrutiny is the role of the
immune system [11–15].
Neuroinflammation has been identified as a mediator
of behavioral alterations and cognitive impairments in
many neurological conditions, including Alzheimer’s
Disease, Major Depression, and injury from cerebral
ischemia [16–18]. The expression of key proinflammatory
mediators such as TNFα, IL-1β, IFN-γ, and IL-6 have been
associated with mood disorders and their administration
has been shown to induce depressive symptoms [19].
In addition to enhanced expression of proinflammatory
cytokines, increased microglial activation, especially in
the limbic system, has been identified as an important
contributor to neuroinflammation in Alzheimer’s disease,
chronic stress, and depressed suicide victims [20–22].
Recent research supports the role of neuroinflammation in
mediating the neurological dysfunction seen with cancer
and cancer treatment [11, 14, 15, 23].
The role of immune activation in cancer-related
neurological dysfunction becomes especially important
when considering cancer therapies which rely in part or
in total on activation of the immune system. The efficacy
of radiation therapy, especially the abscopal response, is
dependent in part on immune activation [24–27]. Direct
radiation of the brain has been repeatedly associated with
behavioral alterations and impairments in hippocampusdependent cognition and neurogenesis, effects which
may be in part mediated by the immune system [28–32].
However, modeling neurological dysfunction following
peripheral radiation in mice has only recently been
explored [11].
In addition to radiation treatment, one of the
most exciting developments in cancer therapeutics,
immunotherapy, also relies on systemic immune activation.
www.impactjournals.com/oncotarget
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stimulation [50, 51], and treatment of cancer-related
neurological dysfunction [52, 53], none have examined
the effects of peripheral radiation in tumor-bearing mice
or of immunotherapy in any tumor state. This is not only
pertinent to understand given the emerging potential of
these therapeutics, but also for the particular insight they
may give to the role of the immune system in general.
This study includes both tumor-free and tumor-bearing
mice, as well as examines the effects of radiation and
immunotherapy both alone and combined (see Figure 1 for
the experimental design). Second, this study involves the
use of newly developed precision irradiation technologies
and the use of distinct genetic backgrounds, which more
closely models clinical relevance. The Small Animal
Radiation Research Platform (SARRP) combines conebeam CT-guided imaging with precise radiation delivery
and an automatically rotatable stage that allows for delivery
of single or multiple beams of radiation to the tumor. This
study models cancer-related cognitive dysfunction in two
mouse models of cancer: BALB/c mice with colorectal
carcinoma and C57BL/6J mice with lung carcinoma.
The colon26 adenocarcinoma (CT26) and Lewis Lung

carcinoma cell lines were chosen because they are known to
secrete IL-6 and TNF-α, do not metastasize when injected
subcutaneously, and have growth curves amenable to this
experimental timeline [54, 55].
The primary objective of this study was to
investigate how checkpoint inhibitor immunotherapy
combined with radiation therapy will affect behavioral
and cognitive performance in tumor-free and tumorbearing mice. Here, we show that the combination of
radiation and immunotherapy enhances tumor control,
but also affects behavioral and cognitive performance,
as well as the inflammatory environment in the brain.
Immunotherapy and radiation alone also seem to alter the
immune environment in the brain, but do not cause the
behavioral and cognitive changes seen with combined
immunotherapy and radiation. Presence of tumor also
affects behavioral and cognitive performance, and the
immune environment in the brain. Collectively, these
studies show that the neuroinflammatory, behavioral, and
cognitive effects of radiation and immunotherapy must
be closely considered in the context of cancer-related
neurological dysfunction.

Figure 1: Control of tumor growth achieved with combined treatments. (A) Tumor visualization and isocenter placement

using a cone-beam CT scan with 360 projections on the SARRP. (B) Delivery of 20 Gy focal radiation to the tumor site using a 10 × 10 mm
collimator at a 50° angle to minimize dose to radiosensitive organs. (C) Growth of individual 3LL tumors in C57BL/6J mice on days 15
to 28 in mice left untreated (NT), treated with radiation (RT) or immunotherapy (IT) alone, or combined treatment (CT). Tumor growth in
mice receiving CT is significantly slowed compared to those receiving NT. Tumor growth in mice receiving RT or IT is not significantly
different than NT. (D) Growth of individual CT26 tumors on days 15 to 28 in BABL/c mice in treatment groups described above. Tumor
growth in mice receiving RT and CT is significantly decreased compared to NT. *p < 0.05, ***p < 0.001 compared to NT, ANOVA,
followed by Dunnett post-hoc (C, n = 10 per group; D, n = 5).
www.impactjournals.com/oncotarget
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Table 1: Body weights, motor function of C57BL/6 with or without 3LL tumors receiving no
treatment, radiation alone, immunotherapy alone, or combined radiation and immunotherapy
Body weight
Tumor status

Treatment

Initial body
weight (g) a

Mean body
weight (g)b

Weight
change (g)c

Motor function
Rotarod latency
to fall (s)d

Open field
velocity (cm/s)e

Tumor-free

NT
19.36 ± 0.67
19.24 ± 0.54
1.34 ± 1.06
52.61 ± 4.82
5.98 ± 0.19
RT
20.72 ± 0.44
19.61 ± 0.58
0.84 ± 0.39
52.37 ± 5.15
5.37 ± 0.34
IT
21.00 ± 0.18
19.96 ± 0.72
1.20 ± 0.39
50.20 ± 4.53
5.47 ± 0.42
CT
19.58 ± 0.08
18.41 ± 0.82
0.96 ± 0.27
51.61 ± 5.22
5.28 ± 0.35
Tumor-bearing
NT
18.62 ± 0.54
18.85 ± 0.42
1.98 ± 0.66
50.30 ± 4.46
5.50 ± 0.33
RT
19.86 ± 0.50
19.26 ± 0.51
1.32 ± 0.42
50.37 ± 5.26
5.38 ± 0.26
IT
19.90 ± 0.49
18.50 ± 1.11
0.76 ± 0.67
53.92 ± 3.84
5.19 ± 0.34
CT
19.56 ± 0.53
19.28 ± 0.45
0.98 ± 0.62
55.30 ± 4.72
5.82 ± 0.34
Data expressed as mean ± SEM.
a
Value given is mean initial body weight for animals in Experiment 2. (n = 5).
b
Value given is mean body weight for animals in Experiment 2. (n = 4–5).
c
Weight change was calculated as weight at the end of testing (day 25) minus weight at inoculation (day 0). (n = 4–5).
d
Rotarod latency to fall is the mean time to fall during each of 9 trials. (n = 10).
e
Open Field Velocity is the mean velocity (cm/s) over the course of three 5 minute exposures to the open field arena. (n = 10).

RESULTS

Decreased measures of anxiety following
combined radiation and immunotherapy

General health and motor function do not differ
between groups

Symptoms of anxiety and anxiety disorders are
significantly more common in cancer patients than the
general population [3, 56]. To assess levels of anxiety
following radiation and immunotherapy, the number of
entries into the center of the open field was analyzed in
BALB/c with colorectal carcinoma (Figure 2A– 2B) and
C57BL/6J with lung carcinoma (Figure 2C). Representative
motion plots of open-field activity in Figure 2A show
that BALB/c animals treated with combined radiation
and immunotherapy crossed more frequently into the
more-anxiety provoking center of the open field. This
indicates decreased measures of anxiety in combination
treated mice as compared to untreated mice (Figure 2B,
p < 0.05, ANOVA). This effect was seen in both tumorfree (TF) and tumor-bearing (TB) mice. However, in
C57BL/6J mice, this decrease in measures of anxiety was
only seen in tumor bearing mice (Figure 2C, p < 0.05,
ANOVA with Dunnett post hoc). Tumor-bearing mice also
showed higher measures of anxiety than tumor-free mice
(p < 0.05, ANOVA). In fact, tumor-bearing mice receiving
CT showed restored levels of anxiety on par with those of
tumor-free mice receiving no treatment (p > 0.05, t test).
Mice receiving either radiation or immunotherapy alone
did not show any significant differences in measures of
anxiety when compared to animals receiving no treatment.
Other measures of behavior did not show effects of
tumor or treatment. Behavioral despair was measured in

There were no apparent differences in phenotype
between the experimental groups, aside from tumor
growth in tumor-bearing groups. Initial body weights and
body weights taken throughout Experiment 2 (Days 7,
9, 11, 14, 18, and 25) showed no significant differences
between groups or within groups across time (Table 1).
All groups performed similarly with regard to exploratory
activity in the open field and sensorimotor function on the
Rotarod (Table 1).

Tumor growth is only controlled in mice
receiving radiation and immunotherapy
To evaluate the effects of radiation and/or
immunotherapy on growth of 3LL lung carcinoma, tumor
measurements (length and width accurately measured
with calipers) were taken throughout Experiment 2
(Days 7, 9, 11, 14, 17, 19, 21, 23, 25, and 28) and tumor
areas calculated (Figure 1C). Only the combination of
anti-CTLA4 checkpoint inhibitor immunotherapy with
20 Gy focal irradiation to the tumor site (referred to as CT)
produced a significant decrease in tumor areas as compared
to no treatment (NT) (p < 0.05, repeated measures). No
significant treatment effects were seen in groups treated
with radiation (RT) or immunotherapy (IT) alone.
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Table 2: Tumor growth and treatment effects are not seen in all behavioral and cognitive measures
Tumor status

Treatment

Forced swim
Percent time
immobile (%)a

Forced swim
Latency to first
immobility (s) b

Tumor-free

Nest ratingc

Fear Conditioning
Baseline motion
(cm/s)d

NT
70.50 ± 3.52
43.85 ± 6.91
19.24 ± 0.54
RT
71.67 ± 3.77
34.86 ± 9.31
19.61 ± 0.58
IT
68.84 ± 5.38
26.80 ± 5.51
19.96 ± 0.72
CT
68.89 ± 4.95
37.41 ± 9.39
18.41 ± 0.82
Tumor-bearing
NT
72.41 ± 4.20
61.15 ± 10.18
18.85 ± 0.42
RT
58.83 ± 7.15
51.72 ± 10.78
19.26 ± 0.51
IT
65.55 ± 2.75
42.98 ± 8.00
18.50 ± 1.11
CT
69.33 ± 3.80
50.25 ± 6.34
19.28 ± 0.45
Data expressed as mean ± SEM.
a
Percent time immobile based on predominant behavior during 5s time-sampling for 300s. (n = 9–10).
b
Latency to first immobility after placement in forced swim chamber. (n = 9–10).
c
Average nest score from three independent raters. (n = 9–10).
d
Average baseline motion (cm/s) during Fear Conditioning Training session. (n = 9–10).

265 ± 25.56
279.9 ± 36.1
271.6 ± 46.66
271.4 ± 26.11
266.5 ± 45.12
269.5 ± 48.08
267.2 ± 46.96
243.4 ± 26.17

Figure 2: Decreased measures of anxiety mice receiving combined treatment (CT) in two different mouse models of
cancer. Number of entries into the center of the open field arena was used as a marker for anxiety behavior. (A) Representative tracks of

open field behavior as recorded in BALB/c mice ± CT26 inoculation left untreated (NT) or treated with CT. (B) Both tumor-free (TF) and
tumor-bearing (TB) BALB/c mice treated with CT demonstrate decreased measures of anxiety. (C) In C57BL/6J mice ± 3LL inoculation,
measures of anxiety are increased in TB mice. However, TB mice treated with CT demonstrate decreased measures of anxiety. *p < 0.05
compared to NT, ANOVA, followed by Dunnett post-hoc. #p < 0.05, ANOVA, effect of tumor. (B–C, n = 10 per group).
www.impactjournals.com/oncotarget
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Experiment 2 by determining the percent time a mouse
spent immobile using the forced swim test, during
which a mouse is introduced into a water-filled cylinder
from which it cannot escape. There were no significant
effects of tumor or treatment in percent time immobile
during the forced swim test (Table 2). However, tumorbearing mice demonstrated a significantly longer latency
to first immobility (Table 2.) Nest building is a natural
rodent behavior that can model disrupted activities of
daily living in people with cognitive impairment [57].
Regardless of tumor status or treatment received, mice in
Experiment 2 demonstrated similar nest building scores
(Table 2). Home-cage activity levels were measured
in Experiment 3 through the use of infrared home-cage
activity sensors across a 28-day period of four intervals:
baseline activity (days –7 to –1), tumor growth (days 0 to
6), post-IT (days 7 to 13), and post-RT (days 14 to 21).
There were no significant effects of tumor or treatment
on mean activity levels in the light or dark throughout the
duration of the experiment (data not shown). Comparing
mice at the tumor-free, no treatment (TF-NT) stage with
mice after three weeks of tumor growth either receiving
no treatment (TB-NT) or combined treatment (TB-CT)
also showed no effect of tumor or treatment on home-cage
activity (Figure 3A). Mean activity patterns also showed
no significant differences (Figure 3B).

conditioned tone. Before the tone, all groups exhibited
similarly low levels of freezing in response to the novel
context (Table 2). However, once the tone was played, mice
with tumors demonstrated decreased freezing as compared
to tumor-free mice (p < 0.05, ANOVA), demonstrating an
impairment in cue-dependent fear memory (Figure 4D).

Immunotherapy elicits enhanced
neuroinflammation including activation of
microglia, but not neuronal degeneration
Microglial activation has been associated with
many neurodegenerative conditions, especially in the
limbic system [20, 21]. CD68 was used as a marker of
the presence of activated microglia in the cortex and
three regions of the hippocampus (CA1, CA3, and
dentate gyrus) in the BALB/c mice with colorectal
carcinoma (Figure 5A) and C57BL/6J mice with lung
carcinoma (Figure 5B– 5C). In BALB/c mice, there was
increased activation of microglia in the cortex, CA1, and
CA3 following combined treatment in tumor-free mice
(p < 0.05 for cortex and CA1; p < 0.01 for CA3; ANOVA
with Dunnett post-hoc test). However, a significant
interaction between treatment and tumor status was
seen when comparing tumor-free to tumor-bearing mice
(p < 0.05 for dentate gyrus, p < 0.01 for cortex, CA1, and
CA3; ANOVA). Tumor-bearing mice receiving combined
treatment had microglial activation levels similar to that
of the tumor-free control (Figure 5A). A similar pattern
of microglial activation was seen in tumor-free C57BL/6J
mice: there was a significant effect of treatment in the
cortex (p < 0.01, ANOVA), CA1 (p < 0.01, ANOVA),
CA3 (p < 0.05, ANOVA), and the dentate gyrus
(p < 0.01, ANOVA). In the dentate gyrus, there was a
significantly higher level of activated microglia in mice
receiving combined treatment compared to no treatment
(p < 0.01, ANOVA with Dunnett posthoc). In the C57BL/6J
mice, however, a different trend emerged in the tumorbearing mice than that seen in BALB/c mice. Here, there
was a significant effect of treatment (Cortex, CA1, and DG
p < 0.01; CA3 p < 0.05, ANOVA). As seen in the tumorfree C57BL/6J mice, there was a significantly higher
level of microglial activation in mice receiving combined
treatment compared to mice receiving no treatment in the
dentate gyrus (p < 0.05, ANOVA with Dunnett posthoc).
Neuroinflammation in the context of cancer and
cancer-treatment is frequently characterized by changes
in expression of proinflammatory cytokines such as
IL- 1β, IFN-γ IL-6, and TNF-α [47, 51]. IFN-γ expression
was decreased in tumor-bearing mice in the cortex
(p < 0.05, ANOVA; Figure 6A). However, IFN-γ levels are
increased in the cortex of tumor-bearing mice following
immunotherapy alone or combined treatments (p < 0.05,
ANOVA). Mice treated with RT show lower levels of IL-6
in the cortex as compared to mice receiving NT (p < 0.05,
ANOVA with Dunnett posthoc). IL-1β and TNF-α levels

Combined radiation and immunotherapy induce
cognitive impairments in some dimensions in
otherwise healthy mice
Novel object recognition was used to assess
cognitive function. Following three acclimation periods,
mice were exposed to two identical objects and allowed to
freely explore (Figure 4A). Twenty-four hours later, mice
were re-introduced to one of the previous familiar objects
and a novel object. Except for the combined treatment
group, all tumor-free mice showed a robust preference for
the novel object (TF-NT, TF-IT p < 0.01; TF-RT p < 0.05,
t test). However, tumor-free mice receiving combined
radiation and immunotherapy displayed impaired object
recognition. Among tumor-bearing mice, only the group
receiving RT demonstrated a preference for exploring the
novel object (p < 0.01, t test) (Figure 4B).
Associative memory was assessed by training
mice to associate a conditioned stimulus (tone) with a
mild foot shock (unconditioned stimulus). Trained mice
demonstrate fear of the conditioned stimulus by freezing
in place [58]. There were no baseline differences in
motion between groups during training (Table 2). To test
contextual memory, mice were exposed to an identical
environment as that encountered during their training.
There were no differences between any of the experimental
groups (Figure 4C). To test cued memory, a Pavloviantype response heavily regulated by the amygdala, mice
were placed in a novel environment and exposed to the
www.impactjournals.com/oncotarget
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in the cortex and hippocampus did not vary with tumor
status or treatment (data not shown). To further evaluate
the neuroinflammatory response seen with peripheral
tumor and combined treatment, a number of other
important proinflammatory cytokines, chemokines, and
growth factors were assessed as well. Of these, IL-5, FGFBasic, and IL-2 showed significant differences between
groups in expression in the cortex. IL-10 was differentially
expressed in the hippocampus (Figure 6B).
In order to study the effect of combined therapy on
T-cell infiltration of the brain, the occurrence of CD3+ T-cells
was assessed via immunohistochemistry. CD3+ T cells
were not observed in brain tissue sections of any group.
Fluoro-Jade C is a marker of degenerating neurons.
There was no Fluoro-Jade C staining in any group.

are most likely at least in part mediated by the immune
environment in the brain [3, 19, 51, 53, 74]. Because
immune activation is at the core of efficacy of critical
cancer therapeutics like radiation and immunotherapy, it is
essential to understand how these treatments may introduce
or exacerbate behavioral changes and cognitive deficits.
This is especially important given durable improvements
in survivorship achieved by checkpoint inhibitor
immunotherapy [44]. We hypothesized that combined
treatment with checkpoint inhibitor immunotherapy and
peripheral radiation treatment would exacerbate cancerrelated neurological dysfunction. In this study, a mouse
model of cancer-related neurological dysfunction was used
to determine the effects of immunotherapy and radiation
treatment on behavioral and cognitive performance, and
neuroinflammation in tumor-free and tumor-bearing mice.
Here we report that although combined treatment achieves
the best tumor control, it is accompanied by behavioral,
cognitive, and neuroinflammatory changes.
One novel finding in this study is the change in
measures of anxiety elicited by combined treatment.
Symptoms of anxiety and depression are significantly

DISCUSSION
Behavioral changes and cognitive impairments
commonly accompany cancer and cancer treatment and
can have a major impact on patient quality of life [59].
These behavioral changes and cognitive impairments

Figure 3: Activity levels do not change with tumor development or treatment with combined immunotherapy and
radiation. (A) Mean activity count was calculated for the light and dark periods of two 48 hr intervals. The first interval was taken over
experimental days -1 and -2 and show mean activity levels immediately before tumor inoculation (TF-NT = tumor-free, no treatment). The
second interval was taken during the last two days of the experiment, days 20 and 21, and shows mean activity levels in tumor-bearing
(TB) mice receiving either no treatment (TB-NT) or combined treatment (TB-CT). There were no significant differences between groups.
(B) Mean activity patterns showing no significant differences between TB-NT and TB-CT mice during the final 84 hours of Experiment 3.
www.impactjournals.com/oncotarget
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more common in cancer patients than in the general
population [3, 56]. In our animal models, the effect of
peripheral tumor alone on measures of anxiety depended
on genetic background and tumor type. C57BL/6J mice
with lung carcinoma displayed increased measures of
anxiety compared to their healthy controls, reflecting
clinical data. However, BALB/c mice with colorectal
carcinoma demonstrated no increase in measures of
anxiety when compared to healthy controls, a finding
which reflects previous studies of behavioral performance
in this tumor model [47]. The lack of increase in measures
of anxiety in BALB/c mice might be due to their generally
lower exploratory activity, making small increases in
measures of anxiety as compared to control mice more
difficult to detect. Although depression is a common
finding in cancer-related neurological dysfunction, our
models did not show differences in percent time spent

immobile between groups on the forced swim test.
Although tumor-bearing mice demonstrated shorter
latency to first immobility, this measure is not typically
analyzed as the first minute of this test is considered
habituation [61, 62]. In future studies, we plan to include
more measures of depression-like behavior, including
those focused on anhedonia.
Another important novel finding in this study is the
cognitive impairment seen with the presence of a peripheral
tumor and combined treatment. Deficits in cognitive
performance, including impairments in executive function,
are frequently reported symptoms in cancer survivors [63,
64]. This cognitive injury has been identified in cancer
patients who have not yet been treated [1, 65]. This clinical
finding was reflected in our mouse model. We saw impaired
performance in both a version of an object recognition test
that is hippocampus-dependent and amygdala-dependent

Figure 4: Combined treatment (CT) and presence of peripheral tumor impair memory. (A) Mice were given access to two

identical objects on Day 1. 24 hours later, mice were reintroduced to one familiar object (F) and one novel object (N). Mice recognizing the
novelty of the new object spent a greater percentage of their time exploring this object. (B) In tumor-free (TF) mice, object recognition was
seen in every group except mice receiving combined treatments (CT). In tumor-bearing (TB) mice, object recognition was only restored in
mice treated with radiation alone (RT). (C) No impairments are seen in a test of contextual fear memory. (D) TB mice show impaired cued
fear memory as compared to TF mice. *p < 0.05, **p < 0.01, (B, n = 10 per group).
www.impactjournals.com/oncotarget
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cued fear memory in mice with tumors. Of the three
treatment arms (radiation alone, immunotherapy alone, and
combined treatment), mice with tumors receiving radiation
alone demonstrated the greatest recovery of cognitive
function following treatment. Interestingly, only combined
treatment with radiation and immunotherapy caused
impairment of object recognition in otherwise healthy mice.
Clinical reports and animal studies indicate that combining

radiation and immunotherapy can result in a particularly
potent anti-tumor effect [41, 66, 67]. Unfortunately, this
potent combination may also have particularly deleterious
effects on behavioral and cognitive performance, as shown
by the pronounced behavioral changes and cognitive
deficits in this group.
There appear to be tumor- or mouse strain- specific
differences in the neurocognitive response to treatment.

Figure 5: Increased presence of CD68+ activated microglia in the hippocampus and cortex following immunotherapy
(IT) or combined treatments (CT). (A) Representative images of CD68 immunostaining in the dentate gyrus (DG) of C57BL/6J

mice ± 3LL inoculation receiving no treatment (NT), radiation alone (RT), immunotherapy alone (IT), or combined treatments (CT).
Quantification of CD68 immunostaining in the cortex and hippocampus (CA1, CA3, DG) of (B) BALB/c mice ± CT26 inoculation or (C)
C57BL/6J mice ± 3LL inoculation receiving NT, RT, IT, or CT. *p < 0.05, **p < 0.01 effect of treatment, ANOVA, followed by Dunnett
post hoc. ^p < 0.05, ^^p < 0.01 interaction, ANOVA, followed by Dunnett post hoc. (B-C, n = 6 per group).
www.impactjournals.com/oncotarget
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The effect of tumor is shown to vary between strains, but
in both cases combined therapy decreased measures of
anxiety. Notably, on some measures, there appears to be a
differential effect of combination therapy based on tumor
status. In the absence of a tumor, combination therapy
increased measures of anxiety and microglial activation,
depending on genetic background. This observation may
have relevance to the very variable individual response
to immunotherapy in patient populations as well as the
variable emergence of toxicities. BALB/c and C57BL/6
mice are prototypical Th2 and Th1 skewed mouse strains
and can have distinct responses to T cell and inflammatory
triggers. These results indicate the importance of including
healthy mice in assessing the effects of combination
therapy on the brain and may have implications for
extended use of these therapies beyond the point of
achieving clinical cure of disease.
Microglial activation appears consistently
increased following treatment with checkpoint inhibitor
immunotherapy, although it is not accompanied by
neuronal injury. Neuroinflammation is a likely mediator
of behavioral changes and cognitive impairments seen
with cancer and cancer treatment [46, 64]. Increased
microglial activation, especially when chronic, has been
associated with neurodegenerative conditions [18]. In
both tumor-free and tumor-bearing mice, there was a
robust increase in microglial activation depending on

the treatment arm. These differences are particularly
striking in the hippocampus, which is similar to findings
of neuroinflammation in chronic stress and depression
[20, 22]. The majority of inflammatory cytokines,
chemokines, and growth factors did not show differences
between groups. We did, however, observe significant
changes based on tumor status in inflammatory cytokines
(IFN-γ, IL-6, IL-5, IL-2, IL-10) and a growth factor (FGFbasic). IFN-γ is a critical inflammatory mediator produced
by chronically activated macrophages [68]. Cortical levels
of IFN-γ were decreased in tumor-bearing mice, but
restored to control levels following combined treatment.
Decreased expression of IL-5, an important regulator of
microglia and infiltrating macrophages in the brain [69],
was also identified in tumor-bearing mice and tumor-free
mice receiving radiotherapy alone. Associations with
IL-5 and cancer-related fatigue have previously been
described clinically [70]. Tumor-free mice receiving
only radiotherapy also demonstrated decreased cortical
expression of IL-6, which has been widely recognized
as one of the most important regulators of neuroimmune
function and has been repeatedly associated with cancerrelated neurological dysfunction [15, 71–73]. Modulation
of the hypothalamic-pituitary-adrenal (HPA) axis is a
likely mechanism for cognitive and behavioral changes
seen with IL-6 expression [74]. Dysregulation of the HPA
axis is strongly linked to changes in emotional behaviors

Figure 6: Effect of peripheral tumor, RT, IT, and CT on cytokine, chemokine, and growth factor levels in the cortex
and hippocampus. (A) Changes in cortex expression of IFN-γ, IL-6, IL-5, FGF-Basic, and IL-2. Lewis lung carcinoma inoculation
induced changes in IFN-γ, IL-5, and FGF-Basic (p < 0.05, ANOVA). There was an effect of interaction of tumor status and treatment on
expression levels of FGF-Basic and IL-2 (p < 0.05 for FGF-Basic, p < 0.01 for IL-2; ANOVA). There was significantly higher expression
of IFN-γ and FGF-Basic in tumor-bearing mice receiving immunotherapy (IT) or combined treatment (CT) compared to mice receiving no
treatment (NT) (p < 0.05, ANOVA with Dunnett posthoc). There was significantly lower expression of IL-6 and IL-5 in tumor-free mice
receiving radiation alone (RT) versus NT (p < 0.05, ANOVA with Dunnett posthoc). (B) Tumor-inoculation increased expression of IL-10
in the hippocampus (p < 0.05, ANOVA). Mice receiving RT demonstrate lower levels of IL-10 in the hippocampus (p < 0.05, ANOVA with
Dunnett posthoc).
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[75] and represents an important potential mechanistic
explanation for the behavioral changes and cognitive
impairments seen in this model. Interestingly, there was
a tumor x treatment interaction for the expression of
both FGF-basic and IL-2 in the cortex. FGF-basic, which
increases with learning and can contribute to recovery from
cognitive injury [76, 77], was decreased in tumor-bearing
mice, except those receiving immunotherapy, either with
or without radiation. IL-2, a hallmark of proinflammatory
polarization [78], demonstrated a robust tumor x treatment
interaction. IL-2 is a potent inducer of vasopressin release
from the hypothalamus [79] and corticotropin-releasing
factor (CRF) from the amygdala [80], demonstrating
another link to dysregulation of the HPA axis in this model.
Finally, IL-10, an important immune inhibitory factor [81],
was increased in tumor-bearing mice, but decreased in the
hippocampus of mice without tumors treated with radiation
only. Taken together, the alterations in expression identified
in cytokines and a growth factor point to a significant role
of dysregulation of the HPA axis as a potential mechanistic
explanation for behavioral and cognitive changes following
neuroinflammation in this model.
In this study, central neuroinflammation was
identified in association with peripheral radiation and
checkpoint inhibitor immunotherapy. In future studies, it
would be important to investigate downstream mediators
of the effects of neuroinflammation on behavioral and
cognitive performance. Previous studies have demonstrated
the potential for immune modulation of neurogenesis,
neurotransmitter metabolism, and the HPA axis as potential
effectors of downstream behavioral and cognitive changes
[11, 20]. Future studies are warranted to investigate
the causative role of neuroinflammation in mediating
behavioral and cognitive effects through the use of antiinflammatory agents in this model.
In our model, no differences were seen in home cage
activity level during the light or dark phases for mice with
tumors, regardless of whether they received combined
immunotherapy and radiation treatment or not. Although
fatigue is another hallmark of cancer-related neurological
dysfunction [82, 83], our finding is consistent with previous
studies showing that home cage activity is stable in the
presence of a peripheral tumor [46, 52]. This also correlates
well with the relatively normal performance of mice with
tumors and treated mice in tests of general locomotor
function and exploratory behavior. These findings indicate
that neither tumor growth nor immunotherapy and radiation
treatment, under the experimental conditions used, cause
dramatic changes in lethargy levels or obvious sickness
behavior, as assessed by analyzing home cage activity.
Likely, the identified impairments are the result of deficits
in higher-level cognition and behavior. We recognize
that it is possible that significant fatigue exists, but is
not exhibited by changes in levels of home-cage activity.
Future studies will utilize voluntary wheel running activity,
which has demonstrated differences in fatigue levels in
www.impactjournals.com/oncotarget

recent models of cancer-related neurological dysfunction
[11, 46, 48, 52, 53].
Cancer-related neurological dysfunction is a
common and devastating consequence of cancer and
cancer-treatment. With improved survivorship and the
emerging use of novel therapeutics that may contribute
to these effects, prevention and treatment of these
behavioral and cognitive impairments is paramount. A
better understanding of the role of the immune system in
mediating these effects will facilitate the development of
treatments to mitigate these effects in the near future.
Developing a model for the behavioral and
cognitive changes following immunotherapy and radiation
treatment allows us to better understand existing clinical
data, expand knowledge of mechanisms, and eventually
develop much-needed therapeutics. Much of the existing
research on cancer-related neurological dysfunction to
date has taken place in breast cancer survivors. Our use
of only female mice reflects the preponderance of human
data available. Utilizing two genetic backgrounds and
tumor types allowed us to examine some of the interindividual and inter-population differences that are often
so significant in translational research projects.
In summary, tumor status has a significant bearing
on the behavioral and cognitive effects of treatments.
Future efforts are warranted to determine how adjuvant
use of immunotherapies may potentiate cancer-related
neurological dysfunction.

MATERIALS AND METHODS
Study Design
The study is divided into three experiments (Figure 7).
The goal of the first experiment was to explore potential
neurological effects of combined immunotherapy and
peripheral irradiation. The goals of the second experiment
were twofold: to determine role of 1) immunotherapy
and radiation individually and 2) variability introduced
by differences in genetic background and tumor type on
neurological effects of combination treatment. Experiment
three was a longitudinal study aiming to examine changes
in circadian rhythm and fatigue through tumor inoculation,
treatment, and recovery. Mice in Experiments 1 and 2 were
transferred from the Earle A. Chiles Research Institute
(EACRI) to Oregon Health and Sciences University
(OHSU) on experimental day 14. Mice in Experiment 3
remained at EACRI. Throughout the project, logistics and
environment were standardized to minimize variation.

Animals
Female two- to four-month-old wild-type BALB/c
(Experiment 1) and C57BL/6J (Experiments 2 and 3) mice
were purchased from the Jackson Laboratory (Bar Harbor,
ME, USA) and allowed to acclimate to their surroundings
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for 7-10 d before experiments. The CT26 and 3LL tumors
models are derived from female mice and therefore
female mice were used by necessity. Female mice are
also preferred due to sexual dimorphism in severity of
phenotype in tumor-bearing mice: male mice demonstrate
greater mortality and weight loss as well as excoriation
of the tumor site [47, 84]. Experiments were performed
with CT26 colorectal carcinoma which is syngeneic to
BALB/c mice and with 3LL lung adenocarcinoma which is
syngeneic to C56BL/6 mice. These cancer cells are grown
in culture and transplanted to immunocompetent syngeneic
mice to generate mouse models of colorectal carcinoma
and lung adenocarcinoma. Subcutaneous tumors permit
accurate radiation targeting and accurate measurement of
response without impeding mouse freedom of motion or
function. Rooms were maintained at 21°C on a 12 h light/
dark cycle with lights on from 06:00 to 18:00. All testing
was performed between 08:00 and 16:00 unless otherwise
noted. Normal chow diet (PicoLab Rodent Diet 20, #5053;
PMI Nutrition International, St. Louis, MO, USA) and tap
water were available ad libitum. All procedures were in
compliance with the National Institutes of Health Guide

for the Care and Use of Laboratory Animals and with
IACUC approval at the EACRI and OHSU.

Cell lines
The CT26 murine colorectal carcinoma [85]
(Experiment 1) and the Lewis lung carcinoma (3LL)
murine cell line [86] (Experiments 2 and 3) were obtained
from the ATCC (Manassas, VA, USA). Stocks were within
3 passages of the ATCC clones with in vitro expansion
used to generate a bank of matched early passage cells
for subsequent experiments. Cells were grown in RPMI1640 media supplemented with HEPES, non-essential
amino acids, sodium pyruvate, glutamine, 10% FBS,
penicillin and streptomycin. All cell lines tested negative
for mycoplasma by ELISA. To initiate tumor growth,
cells were subcutaneously injected into the right flanks
on experimental Day 0 at a dosage of 5 × 105 of CT26
(Experiment 1) or 3LL (Experiments 2 and 3) cells
suspended in 100 µL PBS per animal. Tumor-free mice
were injected with PBS alone using the same procedure.
In experiments 1 and 2, half of mice were tumor-free

Figure 7: Experimental design. (A) Experiment 1 involved four groups: 1) tumor-free (TF), no treatment (NT); 2) TF, combined
treatment (CT); 3) tumor-bearing (TB), NT; 4) TB, CT. (B) Experiment 2 involved eight groups: 1) TF, NT; 2) TF, radiation alone (RT);
3) TF, immunotherapy alone (IT); 4) TF, CT; 5) TB, NT; 6) TB, RT; 7) TB, IT; 8) TB, CT. (C) Experiment 3 involved three longitudinal
groups: 1) TF, NT; 2) TB, NT; 3) TB, CT; with only groups 2 and 3 present at the end of the experiment.
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(TF) and half of mice were tumor-bearing (TB). In
experiment 3, all mice received tumors.

map, was used as a measure of anxiety-like behavior [87].
After each assessment of open-field activity, the equipment
was cleaned with 5% acetic acid to remove residual odors.

Immunotherapy and radiation therapy

Coordination and sensorimotor function
(Rotarod, days 15-17)

On experimental day 7, mice were injected
intraperitoneally with either 250 µg Anti-CTLA4 antibody
(Clone #9D9, BioXCell, West Lebanon, NH) dissolved in
PBS or PBS alone. On experimental day 14, mice received
precision peripheral-irradiation or sham-irradiation using
the Small Animal Radiation Research Platform (SARRP,
XStrahl, Gulmay Medical, Suwanee, GA). Using a
cone-beam CT scan with 360 projections, the tumor was
visualized and isocenter was placed within the tumor.
A single tangent beam using a 5 × 5 mm collimator
was utilized to deliver 20 Gy (Figure 2), as previously
optimized for the CT26 tumor model [39]. In experiment 1,
all mice received either sham treatment (NT) or combined
treatments (CT; 4 groups total; n = 10 mice/group; 40 mice
total). In experiment 2, mice received either NT, peripheralirradiation only (RT), anti-CTLA4 immunotherapy only
(IT), or CT (8 groups total; n = 10 mice/group; 80 mice
total). In experiment 3, mice received either NT or CT
(2 final groups; n = 8 mice/group; 16 mice total).

Mice were placed on an elevated rotating rod
(diameter: 3cm, elevation: 45cm; Rotamex-5, Columbus
Instruments, Columbus, OH, USA) initially rotating at 5.0
RPM. The rod accelerated 1.0 RPM every 3 s. A line of
photobeams beneath the rod recorded the latency to fall
(s). For three consecutive afternoons, each mouse received
three trials per day with no delay between trials.

Object novelty recognition (days 18-19)
The object novelty recognition test relies on rodents’
natural curiosity and propensity to orient their attention
toward a novel stimulus and is sensitive to hippocampal
injury [88]. On day 18, mice were placed into the open
field enclosure, identical to as described above, except
containing two identical objects (small orange hexagonal
prisms) placed 15 cm from the adjacent walls and 10
cm apart (Figure 5). The mice were allowed 10 min to
explore objects. On day 19, one of the identical objects
(“familiar”) was replaced with a novel object (small green
triangular prism) of identical dimensions. Movement and
exploration were tracked and analyzed for nose, body, and
tail with Ethovision XT 7. Nose point location within the
object zone was used to determine exploratory behavior.
Object novelty recognition was determined by calculating
the percent time spent exploring the novel object out of the
time spent exploring the novel and familiar objects.

Behavioral and cognitive testing
Mice in experiments 1 and 2 underwent behavioral
and cognitive testing beginning on experimental day
15. Mice were singly housed 24 hours prior to the first
behavioral test to minimize the effects of social influences
on behavior. As alterations in exploratory behavior and
measures of anxiety might affect performance in cognitive
tests, they were assessed as well. Behavioral testing was
performed in order of increasing stress level [28]. All
behavioral testing was performed by an observer blinded
to treatment group. The sequence of behavioral testing
was: the open field (n = 10 mice/group/experiment),
Rotarod (n = 10 mice/group/experiment), novel object
recognition (n = 10 mice/group/experiment), fear
conditioning (n = 10 mice/group/experiment), and forced
swim test (n = 10 mice/group for Experiment 2).

Associative learning and memory (days 25-26)
In this task, mice learned to associate a conditioned
stimulus (CS, e.g. the environmental context, or a discrete
cue-tone) with a mild foot shock (unconditioned stimulus,
US). CS-US pairings are preceded by a short habituation
period, from which a baseline measure of locomotor
activity and other behavior can be scored. Contextual fear
conditioning is thought of as hippocampus and amygdala
dependent, while fear conditioning to a cue is considered
to be amygdala-dependent but hippocampus-independent
[89, 90]. Post-exposure freezing, defined as somatomotor
immobility with the exception of respiration, is considered
a post-exposure fear response, and is a widely used
indicator of conditioned fear [58]. Mice were trained and
tested using a Med Associates mouse fear conditioning
system (PMED-VFC-NIR-M, Med Associates, St. Albans,
Vermont) utilizing Med Associates VideoFreeze automated
scoring system. Mice were placed inside a brightly lit fear
conditioning chamber (100 lux) and allowed to habituate
for 90 s. The mice were then exposed to a 30 s (80dB) tone
(cue) paired with a 2 s 0.7 mA foot shock administered at

Measures of anxiety and exploratory behavior
(open field, days 15-17)
The open field consists of a brightly lit enclosure
(40.6 x 40.6 cm) with a white plastic floor and clear
Plexiglas walls (Kinder Scientific, Poway, CA). On three
consecutive mornings, mice were allowed to explore the
enclosure for 15 minutes. Movement and exploration were
tracked and analyzed with video software from Noldus
Information Technologies (Ethovision XT 7, Wageningen,
The Netherlands). Distance moved and percent of time
spent in the center of the enclosure were analyzed as
outcome measures. Number of entries into the center of
the enclosure, assessed according to a programmed zone
www.impactjournals.com/oncotarget
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118 s, co-terminating with the tone at 120 s. This series
was repeated for a total of five times. Twenty four hours
later, contextual associative memory was assessed during
re-exposure to the training environment for 300 s. Three
hours later, mice were exposed to a modified environment
(scented with vanilla extract, novel floor texture covering
shock-grid, and a black plastic triangular insert for the
walls), allowed to habituate to it for 90 s, and exposed to
the sound cue for a period of 180 s. Associative learning
was measured as the percent time spent freezing in
response to the contextual environment or tone. Motion
during shock was measured to account for sensor-motor
differences in response to the aversive stimulus.

overnight, and then transferred to 30% sucrose. Fixed
brains were coronally sectioned at 40 µm into five
series using a cryostat (Microm HM505E, MICROM
international GmbH, Walldorf, Germany).

CD-68, CD-3 immunohistochemistry
CD-68 is a selective marker of activated microglia
[95]. Anti-CD3 antibodies can be used effectively as T cell
markers as the CD3 protein complex is a defining feature
of the T-cell lineage [96]. Coronal brain sections were
processed for immunohistochemical detection of CD68 or CD-3. Sections were rinsed in PBS, incubated in
5% normal goat serum and 0.3% Triton-X in PBS (PBSTX) for 90 min, rinsed again with PBS, and incubated in
primary antisera (CD-68 rat monoclonal: 1:500, Abcam,
ab53444, Eugene, OR, USA; CD-3 hamster monoclonal:
1:50, BD Biosciences, 550277, San Jose, CA, USA) in
5% normal goat serum and PBS-TX overnight at 21°C.
Sections were then rinsed in PBS and incubated for 2 h in
biotinylated goat-anti-rat antibody (for CD-68; 1:200; Life
Technologies, Eugene, OR, USA) or goat-anti-hamster
antibody (for CD-3; 1:200; Invitrogen, Carlsbad, CA,
USA) in PBS-TX. Following rinses in PBS, sections were
immediately mounted on slides and coverslipped 3 h later
with Vectashield Antifade Mounting Medium with DAPI
(Vector Laboratories, Burlingame, CA, USA).

Depression-like behavior (day 27)
The forced swim test is commonly used to assess
depression-like behavior in animals. It assesses degree of
learned helplessness or behavioral despair as determined by
the scoring of active (swimming and climbing) versus passive
(immobility) behaviors in an inescapable cylinder filled with
water [91–93]. In this procedure, mice were placed in cylinders
filled with water (24°C to a depth of 15 cm) for 6 minutes
and recorded. For the last five minutes of the trial, mice were
scored as either immobile or mobile every 5 s. The mice were
considered immobile once three paws were immobile and the
fourth paw exhibited only minimal movement. Behavioral
despair was measured as percent time spent immobile.

Fluoro-Jade C staining

Activity monitoring and nest building

Fluoro-Jade C can be used to identify degenerating
neurons, regardless of mechanism of injury [97]. Coronal
brain sections were prepared for Fluoro-Jade C staining.
The sections were mounted on slides and allowed to dry.
Slides were immersed in 80% ethanol with 1% NaOH for
5 min followed by a 2 min soak in 70% ethanol and 2 min
soak in distilled water. The slides were then incubated in
0.06% potassium permanganate for 15 min, followed by
a 2 min soak in distilled water, and 30 min incubation in
0.0001% Fluoro-Jade C working solution. The 0.0001%
working solution of Fluoro-Jade C was prepared by adding
10 mL of the stock Fluoro-Jade C solution (0.01%) to
990mL of 0.1% acetic acid in distilled water [97]. The
working solution was used within 2 h of preparation.
The slides were then rinsed in distilled water and air
dried overnight. The air dried slides were then cleared in
xylene for 2 min two times before being coverslipped with
Permount (VWR, Visalia, CA, USA).

For home cage activity monitoring (Experiment 3),
16 mice were monitored for activity levels using infrared
home-cage activity sensors (Biobserve, St. Augustin,
Germany). Mice were housed and acclimated to the
home-cage environment for three days prior to beginning
activity measurement. All 16 mice received 3LL tumor
injections one week later. Eight mice were treated with
the protocol described above (anti-CTLA4 on day 7, RT
on day 14). Activity counts (beam breaks) were measured
every second for four weeks and data were expressed as
mean activity count per hour. Due to technical problems,
data for days 4, 10-13, and 17 were lost. Nest building
was measured in Experiments 1 and 2 using an established
protocol [94]. Briefly, mice were individually housed in
a clean cage and provided two pressed cotton squares
(Ancare, Bellmore, NY, USA). Photos of the home cage
were taken 48 h later and visually rated by three different
blinded scorers on a 5-point nest rating scale.

Cytokine bead assay

Histological evaluation

For cytokine bead assays, cortical and hippocampal
tissues were collected from 4 mice per group from
Experiment 2. 25-300 mg of tissue was homogenized in
4.5µL of ice cold PBS containing cOmplete EDTA-free
Protease Inhibitor Cocktail (Roche Diagnostics USA,
Indianapolis, IN, USA) per mg of tissue. Homogenates

For histological evaluation, 6 mice from each group
from Experiments 1 and 2 were intracardially perfused
on experimental day 28 with 20-mL phosphate-buffered
saline (PBS) followed by 40mL 4% paraformaldehyde.
Brains were removed, stored in 4% paraformaldehyde
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